News

This Skin Cancer Awareness Month, we have compiled a list of resources for clinicians to share with their patients.

Researchers explored the risk of SPM in patients of different races with the rare type of tumor of the skin.

VYNE expects to enroll the first patient with vitiligo in the phase 2b trial for VYN201 in the second quarter of 2024.

Authors of a recent review concluded that combining various therapies holds promise in the treatment of acne scarring.

Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.

Renata Block, MMS, PA-C, shares her favorite topics from the aesthetic conference held last month.

A prebiotic cleanser and moisturizer regimen not only significantly alleviated the severity of atopic dermatitis and xerosis, but also uncovered crucial differences in symptom experiences.

Topical Bacitracin, Neosporin, and Vaseline were applied to mice over a 6-week period.

The awarded grant will span a total of 3 years.

Aaron Farberg, MD, discusses the low-dose, affordable Accutane treatment and Clear Health’s mission to improve patient access to affordable acne therapies.

Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.

Dermatology Times' Spring Editor in Chief, Aaron Farberg, MD, discusses the business strategy known as buy and bill.

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

In addition, authors of a research letter noted that patients with vitiligo demonstrated a comparable risk of myocardial infarction and cerebrovascular accident.

Brian Kim, MD, had an unexpected attendee at one of his AAD sessions and delves into what's new, what's now, and what's next in atopic dermatitis management.

Marc Hurlbert, PhD, discusses how the Melanoma Research Alliance works with dermatology clinicians to provide fundings and resources for melanoma research.

Researchers found that the diameter of cutaneous melanoma demonstrated a weak positive correlation with tumor thickness.

Dozens of investigators shared findings to advance care in patients with melanoma during Mohs micrographic surgery.

The Harris brothers serve 2 predominantly elderly populations and appreciate the opportunity to provide solutions for the growing complexity of skin cancer issues as patients live longer.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month and Melanoma Monday.

Keep up with the latest headlines in dermatology from the past week, including the invention of a groundbreaking method for detecting skin cancer using Terahertz waves, a survey indicative of young people's perceptions of sun exposure, and more.

In case you missed it, this week we had news about Dermavant's FDA-accepted sNDA for tapinarof cream 1% for AD, Eli Lilly's resubmitted BLA for lebrikizumab for AD, Rosacea Awareness Month recaps, and more.

This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC.

Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.

Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.

Earlier this week, we shared our fourth and final Rosacea Awareness Month quiz. Review the answers and your responses below.

May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life, and well-being.

A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.

The new research will compare eblasakimab to dupilumab and lebrikizumab.